#United States #New Haven #Trevi Therapeutics #Haduvio #chronic cough

Trevi Therapeutics Highlights Participation in March Investor Conferences

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical biopharmaceutical company targeting chronic cough treatments, has announced its active participation in several prominent investor conferences this coming March. The company is notably focused on its investigational therapy, Haduvio™ (oral nalbuphine ER), aimed at addressing chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Upcoming Conference Schedule

Trevi's senior management team will be on-site at the following events:

1. TD Cowen 45th Annual Health Care Conference
- Dates: March 3-5, 2025
- Location: Boston, Massachusetts
- Presentation: March 4, 10:30-11:00 AM ET
- Representatives: Lisa Delfini (CFO) and Farrell Simon (CCO)
This conference will serve as an ideal platform for Trevi to present their latest advances and strategic insights.

2. Leerink Partners Global Healthcare Conference
- Dates: March 10-12, 2025
- Location: Miami, Florida
- Presentation: March 12, 8:00 AM ET
- Representatives: Jennifer Good (CEO) and James Cassella (CDO)
This venue will focus on the opportunities presented by Haduvio for treating chronic cough, allowing investors to gain a deeper understanding of Trevi's mission and vision.

3. Leerink Partners Mountain Meeting
- Dates: March 23-26, 2025
- Location: Jackson Hole, Wyoming
- Representative: Lisa Delfini (CFO)
In this setting, Trevi aims to foster relationships and insights that could further impact the treatment landscape for chronic cough.

About Haduvio™

Haduvio™ is currently a focal point of Trevi Therapeutics' research efforts. This investigational therapy utilizes oral nalbuphine extended-release to manage persistent cough experienced by individuals suffering from IPF—an area lacking effective treatment options. Chronic cough affects an alarming 85% of IPF patients, with significant repercussions on their quality of life. Given that around 140,000 individuals in the U.S. have IPF, the pressure for viable therapeutic solutions is immense.

Haduvio operates by targeting the cough reflex both centrally and peripherally, utilizing kappa agonist and mu antagonist functions of opioid receptors. This innovative mechanism is designed to mitigate cough hypersensitivity—a cornerstone of chronic cough pathology. The complications arising from chronic cough can severely affect patients' social, physical, and psychological well-being, making Haduvio's potential approval instrumental.

Additionally, refractory chronic cough impacts approximately 2-3 million adults nationally, complicating their everyday lives. Without approved therapies to alleviate this condition currently, Trevi's initiative may pave the path toward groundbreaking updates in treatment protocols.

Conclusion

The upcoming conferences in March represent a pivotal moment for Trevi Therapeutics as they look to increase awareness and investment interest in their innovative therapeutic approaches. With no current FDA-approved treatments for chronic cough in either IPF or RCC patients, Trevi's focused efforts hold promise for changing the treatment landscape significantly. For further details and developments from Trevi, please visit Trevi Therapeutics or follow the company on X (formerly Twitter) and LinkedIn.

Investor & Media Contacts

For investor inquiries, reach out to Jonathan Carlson at Trevi Therapeutics, or for media concerns, contact Rosalia Scampoli. Both contacts are detailed in Trevi’s latest announcements.